论文部分内容阅读
目的观察曲美他嗪治疗冠心病合并左心室舒张功能不全的临床效果。方法将冠心病合并左心室舒张功能不全患者80例随机分为观察组和对照组各40例。对照组行常规治疗方法,观察组在常规治疗的基础上加用曲美他嗪治疗。对比2组患者治疗效果、治疗前后左心室射血分数(LVEF)、舒张早、晚期血流峰值(E、A)及二者比值(E/A)、二尖瓣口及二尖瓣环舒张早期峰值速度比值(E/e’)。结果观察组总有效率为87.5%显著高于对照组的65.0%,差异有统计学意义(P<0.05)。治疗前2组LVEF、E、A、E/A、E/e’水平差异无统计学意义(P>0.05)。治疗后2组LVEF、E、E/A均显著增加,A、E/e’均显著降低,且观察组各指标变化幅度均大于对照组,差异均有统计学意义(P<0.05)。结论曲美他嗪治疗冠心病合并左心室舒张功能不全疗效显著,可有效改善患者心室舒张功能,具有一定临床价值,值得推广运用。
Objective To observe the clinical effect of trimetazidine on patients with coronary heart disease complicated with left ventricular diastolic dysfunction. Methods 80 patients with coronary heart disease complicated with left ventricular diastolic dysfunction were randomly divided into observation group and control group, 40 cases each. The control group underwent routine treatment. The observation group was treated with trimetazidine on the basis of routine treatment. The therapeutic effect was compared between the two groups. The left ventricular ejection fraction (LVEF), early diastolic and late peak blood flow (E, A) and their ratio (E / A), mitral and mitral annular dilatation Early peak velocity ratio (E / e ’). Results The total effective rate of the observation group was 87.5%, which was significantly higher than that of the control group (65.0%), the difference was statistically significant (P <0.05). There was no significant difference in the levels of LVEF, E, A, E / A and E / e between the two groups before treatment (P> 0.05). After treatment, the LVEF, E, E / A in both groups were significantly increased, A, E / e ’were significantly decreased, and the changes in the indicators of the observation group were greater than the control group, the difference was statistically significant (P <0.05). Conclusion Trimetazidine treatment of coronary heart disease with left ventricular diastolic dysfunction significant effect, can effectively improve the patient’s ventricular diastolic function, has some clinical value, it is worth promoting the use of.